Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

2.

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J.

Mult Scler. 2019 Jun 18:1352458519852100. doi: 10.1177/1352458519852100. [Epub ahead of print]

PMID:
31208265
3.

Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases.

Sander L, Pezold S, Andermatt S, Amann M, Meier D, Wendebourg MJ, Sinnecker T, Radue EW, Naegelin Y, Granziera C, Kappos L, Wuerfel J, Cattin P, Schlaeger R; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2019 Jun 17. doi: 10.1002/hbm.24687. [Epub ahead of print]

PMID:
31206931
4.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
5.

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.

Sprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J, Poole EM, Cavalier S.

Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722. [Epub ahead of print]

PMID:
31198103
6.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 May 24;33:131-138. doi: 10.1016/j.msard.2019.05.014. [Epub ahead of print]

7.

Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.

D'Souza M, Heikkilä A, Lorscheider J, Haller V, Kravalis K, Gysin S, Fuertes NAC, Fricker E, Lam E, Higgins P, Tomic D, Papadopoulou A, Kappos L.

Mult Scler. 2019 May 7:1352458519845108. doi: 10.1177/1352458519845108. [Epub ahead of print]

PMID:
31060429
8.

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.

Zimmermann M, Rose N, Lindner JM, Kim H, Gonçalves AR, Callegari I, Syedbasha M, Kaufmann L, Egli A, Lindberg RLP, Kappos L, Traggiai E, Sanderson NSR, Derfuss T.

Front Immunol. 2019 Apr 16;10:829. doi: 10.3389/fimmu.2019.00829. eCollection 2019.

9.

Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Papadopoulou A, Gaetano L, Pfister A, Altermatt A, Tsagkas C, Morency F, Brandt AU, Hardmeier M, Chakravarty MM, Descoteaux M, Kappos L, Sprenger T, Magon S.

Neurology. 2019 May 7;92(19):e2240-e2249. doi: 10.1212/WNL.0000000000007450. Epub 2019 Apr 10.

PMID:
30971483
10.

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.

Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ.

Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.

11.

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Köndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS.

Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.

PMID:
30844611
12.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

13.

Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.

Steinheimer S, Dorn JF, Morrison C, Sarkar A, D'Souza M, Boisvert J, Bedi R, Burggraaff J, Kontschieder P, Dahlke F, Sellen A, Uitdehaag BMJ, Kappos L, Kamm CP.

Disabil Rehabil. 2019 Feb 20:1-7. doi: 10.1080/09638288.2018.1563832. [Epub ahead of print]

PMID:
30782055
14.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

15.

Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study.

Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, Hartmann J, Seifert CL, Poppert H, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Neuroimage. 2019 Apr 1;189:727-733. doi: 10.1016/j.neuroimage.2019.01.052. Epub 2019 Jan 24.

PMID:
30685330
16.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
17.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T.

JAMA Neurol. 2019 Jan 7. doi: 10.1001/jamaneurol.2018.4239. [Epub ahead of print]

PMID:
30615019
18.

Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.

Ruberte E, Sinnecker T, Amann M, Gaetano L, Naegelin Y, Penner IK, Kuhle J, Derfuss T, Kappos L, Granziera C, Wuerfel J, Yaldizli Ö.

Eur Neurol. 2018;80(3-4):207-214. doi: 10.1159/000495798. Epub 2019 Jan 3.

PMID:
30605898
19.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

PMID:
30587516
20.

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.

Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL.

Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117. [Epub ahead of print]

PMID:
30566027
21.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

22.

Learning ability correlates with brain atrophy and disability progression in RRMS.

Sormani MP, De Stefano N, Giovannoni G, Langdon D, Piani-Meier D, Haering DA, Kappos L, Tomic D.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):38-43. doi: 10.1136/jnnp-2018-319129. Epub 2018 Oct 15.

23.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
24.

Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.

Pröbstel AK, Thanei M, Erni B, Lecourt AC, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribi C, Chizzolini C, Kappos L, Trendelenburg M, Derfuss T.

Rheumatology (Oxford). 2018 Sep 27. doi: 10.1093/rheumatology/key282. [Epub ahead of print]

PMID:
30265368
25.

Design and construction of an innovative brain phantom prototype for MRI.

Altermatt A, Santini F, Deligianni X, Magon S, Sprenger T, Kappos L, Cattin P, Wuerfel J, Gaetano L.

Magn Reson Med. 2019 Feb;81(2):1165-1171. doi: 10.1002/mrm.27464. Epub 2018 Sep 17.

PMID:
30221790
26.

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.

Nakamura Y, Gaetano L, Matsushita T, Anna A, Sprenger T, Radue EW, Wuerfel J, Bauer L, Amann M, Shinoda K, Isobe N, Yamasaki R, Saida T, Kappos L, Kira JI.

J Neuroinflammation. 2018 Sep 5;15(1):255. doi: 10.1186/s12974-018-1295-1.

27.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
28.

Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM.

Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690. [Epub ahead of print]

29.

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L.

Ann Neurol. 2018 Oct;84(4):527-536. doi: 10.1002/ana.25313.

30.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
31.

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.

D'Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, Burggraaff J, van Munster CE, Diederich M, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, Kappos L.

Mult Scler J Exp Transl Clin. 2018 Aug 9;4(3):2055217318792399. doi: 10.1177/2055217318792399. eCollection 2018 Jul-Sep.

32.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
33.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
34.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

35.

Spinal cord volume loss: A marker of disease progression in multiple sclerosis.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K.

Neurology. 2018 Jul 24;91(4):e349-e358. doi: 10.1212/WNL.0000000000005853. Epub 2018 Jun 27.

PMID:
29950437
36.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
37.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators.

Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.

38.

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.

Altermatt A, Gaetano L, Magon S, Häring DA, Tomic D, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Brain Topogr. 2018 Sep;31(5):886-894. doi: 10.1007/s10548-018-0652-9. Epub 2018 May 29.

PMID:
29845492
39.

Preferential spinal cord volume loss in primary progressive multiple sclerosis.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K.

Mult Scler. 2019 Jun;25(7):947-957. doi: 10.1177/1352458518775006. Epub 2018 May 21.

PMID:
29781383
40.

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö.

Mult Scler. 2018 May;24(6):777-785. doi: 10.1177/1352458518768433. Epub 2018 Apr 24.

PMID:
29685071
41.

Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum.

Naegelin Y, Dingsdale H, Säuberli K, Schädelin S, Kappos L, Barde YA.

eNeuro. 2018 Mar 22;5(2). pii: ENEURO.0419-17.2018. doi: 10.1523/ENEURO.0419-17.2018. eCollection 2018 Mar-Apr.

42.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group.

Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.

PMID:
29582852
43.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
44.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

45.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

46.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
47.

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T.

Neurology. 2018 Apr 10;90(15):e1324-e1332. doi: 10.1212/WNL.0000000000005292. Epub 2018 Mar 14.

PMID:
29540589
48.

Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].

Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.

Clin Ther. 2018 May;40(5):812. doi: 10.1016/j.clinthera.2018.02.005. Epub 2018 Mar 7. No abstract available.

PMID:
29523369
49.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9.

PMID:
29521573
50.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337

Supplemental Content

Loading ...
Support Center